Degenerative Disc Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Degenerative Disc Disease Pipeline Drugs Market Overview
Degenerative disc disease pipeline drugs market research report provides comprehensive information on the therapeutics under development for Degenerative Disc Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects.
Key Targets in the Degenerative Disc Disease Pipeline Drugs Market
The key targets in the degenerative disc disease pipeline drugs market are Nuclear Factor Kappa B, Interleukin 1 Receptor, Interleukin 10, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, and TGF Beta Receptor Type 1. Nuclear Factor Kappa B has the highest number of pipeline products.
Degenerative Disc Disease Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Degenerative Disc Disease Pipeline Market
The key MoA in the degenerative disc disease pipeline market are Nuclear Factor Kappa B Inhibitor, Interleukin 1 Receptor Antagonist, Interleukin 10 Activator, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, and TGF Beta Receptor Type 1 Antagonist. Nuclear Factor Kappa B Inhibitor has the highest number of pipeline products.
Degenerative Disc Disease Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Degenerative Disc Disease Pipeline Market
The key RoA in the degenerative disc disease pipeline market are parenteral, intrathecal, topical, intravenous, transdermal, intraarticular, intracoronary, and intravitreal. Parental has the highest number of pipeline products.
Degenerative Disc Disease Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Degenerative Disc Disease Pipeline Drugs Market
The key molecule types in the degenerative disc disease pipeline drugs market are cell therapy, small molecule, biologic, gene therapy, oligonucleotide, gene-modified cell therapy, and synthetic peptide. Cell therapy has the highest number of pipeline products in the degenerative disc disease pipeline market.
Degenerative Disc Disease Pipeline Drugs Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the Degenerative Disc Disease Pipeline Market
The key companies in the degenerative disc disease pipeline market are CHA Biotech Co Ltd, AnGes Inc, DiscGenics Inc, Amplicore Inc, Angitia Biopharmaceuticals, Bone Therapeutics SA, FibroGenesis LLC, and Genequine Biotherapeutics GmbH. CHA Biotech Co Ltd has the highest number of pipeline products.
Degenerative Disc Disease Pipeline Market, by Companies
To know about companies, download a free report sample
Market report overview
| Key targets | Nuclear Factor Kappa B, Interleukin 1 Receptor, Interleukin 10, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, and TGF Beta Receptor Type 1 |
| Key MoA | Nuclear Factor Kappa B Inhibitor, Interleukin 1 Receptor Antagonist, Interleukin 10 Activator, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, and TGF Beta Receptor Type 1 Antagonist |
| Key RoA | Parenteral, Intrathecal, Topical, Intravenous, Transdermal, Intraarticular, Intracoronary, and Intravitreal |
| Key molecule types | Cell Therapy, Small Molecule, Biologic, Gene Therapy, Oligonucleotide, Gene-Modified Cell Therapy, and Synthetic Peptide |
| Key companies | CHA Biotech Co Ltd, AnGes Inc, DiscGenics Inc, Amplicore Inc, Angitia Biopharmaceuticals, Bone Therapeutics SA, FibroGenesis LLC, and Genequine Biotherapeutics GmbH |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AnGes Inc
Angitia Biopharmaceuticals
Bone Therapeutics SA
CHA Biotech Co Ltd
DiscGenics Inc
FibroGenesis LLC
Genequine Biotherapeutics GmbH
Histogen Inc
Kolon TissueGene Inc
Locate Bio Ltd
Notogen Inc
Rudacure Co Ltd
Spine BioPharma LLC
Stayble Therapeutics AB
Techfields Pharma Co Ltd
U.S. Stem Cell Inc
Xalud Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the degenerative disc disease pipeline market?
The key targets in the degenerative disc disease pipeline market are Nuclear Factor Kappa B, Interleukin 1 Receptor, Interleukin 10, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, and TGF Beta Receptor Type 1.
-
What are the key MoA in the degenerative disc disease pipeline market?
The key MoA in the degenerative disc disease pipeline market are Nuclear Factor Kappa B Inhibitor, Interleukin 1 Receptor Antagonist, Interleukin 10 Activator, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, and TGF Beta Receptor Type 1 Antagonist.
-
What are the key RoA in the degenerative disc disease pipeline market?
The key RoA in the degenerative disc disease pipeline market are parenteral, intrathecal, topical, intravenous, transdermal, intraarticular, intracoronary, and intravitreal.
-
What are the key molecule types in the degenerative disc disease pipeline market?
The key molecule types in the degenerative disc disease pipeline market are cell therapy, small molecule, biologic, gene therapy, oligonucleotide, gene-modified cell therapy, and synthetic peptide.
-
What are the key companies in the degenerative disc disease pipeline market?
The key companies in the degenerative disc disease pipeline market are CHA Biotech Co Ltd, AnGes Inc, DiscGenics Inc, Amplicore Inc, Angitia Biopharmaceuticals, Bone Therapeutics SA, FibroGenesis LLC, and Genequine Biotherapeutics GmbH.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Musculoskeletal Disorders reports